At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
high-dose ranibizumab +1 moredrug
Likely dose
high-dose ranibizumab 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively
In Brief
A Phase 2 clinical trial evaluating high-dose ranibizumab and ranibizumab for PCV and Polypoidal Choroidal Vasculopathy. Completed, enrolled 24 participants across 3 sites.
Detailed Summary
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPCV, Polypoidal Choroidal Vasculopathy
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedJun 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedJun 24, 2013
Enrollment StartNov 1, 2010
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.0 years ago
Interventions
high-dose ranibizumabdrug
20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
ranibizumabdrug
3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly